Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Published byConstance Bédard Modified over 6 years ago

Similar presentations

Presentation on theme: "Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported."— Presentation transcript:

1 Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. SF-6D: preference-based single index health measure; PCS: physical component summary; HAQ-DI: Health Assessment Questionnaire-Disability Index; MCID: minimum clinically important difference. VIBEKE STRAND et al. J Rheumatol 2012;39: ©2012 by The Journal of Rheumatology

Download ppt "Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported."

Similar presentations

How Much Improvement in Functional Status Is Considered Important by Patients With Active Psoriatic Arthritis: Applying the Outcome Measures in Rheumatoid.

How Much Improvement in Functional Status Is Considered Important by Patients With Active Psoriatic Arthritis: Applying the Outcome Measures in Rheumatoid.
Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.

Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.
Patient-Reported Physical Functioning Ron D. Hays November 27, 2012 (11:15-11:30) UCLA Department of Medicine MCID for Orthopaedic Devices Silver Springs,

Patient-Reported Physical Functioning Ron D. Hays November 27, 2012 (11:15-11:30) UCLA Department of Medicine MCID for Orthopaedic Devices Silver Springs,
SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden,

SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden,
Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.
Percentage of patients achieving DAS28 (CRP) < 3

Percentage of patients achieving DAS28 (CRP) < 3
Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.
End point Fenoldopam, n (%) Dopamine, n (%) p

End point Fenoldopam, n (%) Dopamine, n (%) p
Updated 2016 PsA Core Domain Set.

Updated 2016 PsA Core Domain Set.
Clinical responses over time.

Clinical responses over time.
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Similar presentations

Ads by Google